Huale Zhang

Huale Zhang


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2025 in BMC Pregnancy and Childbirth
Verified
Journal Article
Open access
PDF file
QHQing Han
Qing Han
SZShuisen Zheng
Shuisen Zheng
XCXiaoling Chen
Xiaoling Chen
YGYuting Gao
Yuting Gao
HZHuale Zhang
Huale Zhang
NLNa Lin
Na Lin
We aimed to investigate the relationship between the prognostic nutritional index (PNI) during the third trimester and the risk of preeclampsia (PE) in twin pregnancies. A total of 2998 twin pregnancies were enrolled in Fujian Maternal and Child Health Hospital from January 2015 to December 2021, including preeclampsia group (n = 421) and control group (n = 2577). The significance of the characteristic variables in predicting PE in twin pregnancies were calculated using the random forest algorithm (Boruta package) and the correlation between PNI and PE in twin pregnancies was examined in three distinct models using multivariable logistic regression corrected for confounders. Receiver operating characteristics (ROC) curves were used to evaluate the ability for PNI to predict PE in twin pregnancies. PNI (37.92 ± 3.86 vs. 40.57 ± 3.63, P < 0.001) was significantly lower in the PE group than in the control group. After adjusting for all covariates, the PNI was negatively associated with PE in twin pregnancies (OR = 0.780; 95% CI: 0.753, 0.808). Meanwhile, the higher PNI remained an independent protective factor for PE in twin pregnancies compared to lower PNI (OR, 95% CI: 0.410, 0.438–0.530; 0.144, 0.103–0.201) in sensitivity analysis. ROC curve analysis revealed an area under curve (AUC) of 0.691 for PNI and the cut-off value of PNI was 40.162. PNI was negatively correlated with the risk of PE in twin pregnancies, which may help in risk assessment for twin pregnancies. Not applicable.

15 November 2022 in Frontiers in Endocrinology
Verified
Journal Article
Open access
WJWenwen Jiang
Wenwen Jiang
BZBei-Hong Zhen
Bei-Hong Zhen
XLXiuhua Liao
Xiuhua Liao
XCXiaojing Chen
Xiaojing Chen
SZSuqin Zhu
Suqin Zhu
HZHuale Zhang
Huale Zhang
Objective: To explore the relative factors for best ovarian response in patients undergoing assisted reproductive technology with the gonadotropin-releasing hormone antagonist protocol and to establish a nomogram prediction model of ovarian response.Methods: A retrospective cohort analysis of the clinical data of 1,944 patients who received assisted reproductive treatment in the Center for Reproductive Medicine of Fujian Maternity and Child Health Hospital from April 1, 2018, to June 30, 2020. According to the number of oocytes obtained, there were 659 cases in the low ovarian response group (no more than five oocytes were retrieved), 920 cases in the normal ovarian response group (the number of retrieved oocytes was >5 but ≤18), and 365 cases in the high ovarian response group (>18 oocytes retrieved). Independent factors affecting ovarian responsiveness were screened by logistic regression, which were the model entry variables, and a nomogram prediction model was established based on the regression coefficients.Results: There were statistically significant differences in age, anti-Mullerian hormone, antral follicle count, the diagnosis of endometriosis, decreased ovarian reserve, polycystic ovary syndrome, basal follicle-stimulating hormone and basal luteinizing hormone among the three groups (P < 0.001). Multifactorial stepwise regression analysis showed that female age (0.95 [0.92–0.97], P = 0.000), decreased ovarian reserve (0.27 [0.19-0.38]), P = 0.000), endometriosis (0.81 [0.56-0.86], P = 0.000), antral follicle count (1.09 [1.06-1.12], P = 0.000), basal follicle-stimulating hormone (0.90 [0.85-0.96], P = 0.001), Anti-Mullerian hormone (1.19 [1.13–1.26], P= 0.000) and luteinizing hormone on trigger day (0.73 [0.66–0.80], P= 0.000), were independent factors for the occurrence of different ovarian responses during ovarian hyperstimulation. The predictive model of ovarian responsiveness was constructed based on the above factors, and the model was verified with 589 patients’ data from July 1, 2020, to December 31, 2020, at this center. The predicted ovarian response (number of eggs obtained) of a total of 450 patients was consistent with the actual results, with a coincidence degree of 76.4%, and the consistency index of the model is 0.77.Conclusion: The nomogram model was successfully developed to effectively, intuitively, and visually predict the ovary reactivity in the gonadotropin-releasing hormone antagonist protocol and provide guidance for clinical practice.

18 May 2023 in Asian Journal of Surgery
Verified
Journal Article
Open access
HWHongMei Wang
HongMei Wang
YPYi Peng
Yi Peng
JWJianbin Wu
Jianbin Wu
ZCZhuangWei Chen
ZhuangWei Chen
HZHuale Zhang
Huale Zhang
Adjuvant chemotherapy (AC) is an important, effective treatment for breast cancer. This study evaluates the effectiveness of post-mastectomy AC in treating patients with prognostic stage IB breast cancer. We conducted a retrospective cohort-based study using Surveillance, Epidemiology, and End-Results database. Overall survival (OS) and breast cancer-specific survival (BCSS) were calculated using the Kaplan-Meier method. Multivariate Cox risk models were used to identify the impact of AC. Stratified analysis was performed according to molecular subtypes, anatomic stages, and other risk factors to evaluate the effect of AC on survival. 28,825 women diagnosed with prognostic stage IB breast cancer were included. The 5-year OS was significantly higher in AC group than in non-adjuvant chemotherapy (NAC) group (P < 0.0001); however, the 5-year BCSS in AC group was significantly lower than in NAC group (P = 0.039). Multivariate analysis revealed that AC was a favorable prognostic factor for OS (P < 0.001), but not BCSS (P = 0.407). AC was not an independent prognostic factor for BCSS in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR[+]/HER2[-]) subtype or pT1a-1b/N0-1 stage with HER2 overexpression (HER2[+]) subtype, regardless of whether HR was positive or negative (P > 0.05). Meanwhile, AC is not an independent prognostic factor for OS and BCSS in patients with lymph node micrometastases. Our study demonstrates that patients with prognostic stage IB do not fully benefit from AC. Individualized treatment management is required for patients with pT1a-1b/N0-1 tumors, lymph node micrometastases, or HR(+)/HER2(-) subtypes.

1 December 2025 in Translational Cancer Research
Verified
Journal Article
Open access
PDF file
HZHuale Zhang
Huale Zhang
YZYue Hui Zhou
Yue Hui Zhou
GLGu Bin Lin
Gu Bin Lin
BZBi Lian Zheng
Bi Lian Zheng
KZKun Zhang
Kun Zhang
HZHua Le Zhang
Hua Le Zhang
Background: In the case of lymph node metastasis, small-tumor breast cancer patients show distinct survival rates. Current studies have not conducted in-depth analyses of small-tumor patients with different immune subtypes and different lymph node metastases. This study aimed to examine the survival outcomes and chemotherapy efficacy of patients with different immune subtypes. Methods: Retrospective clinical data of small-tumor breast cancer patients were obtained from the Surveillance, Epidemiology, and End Results (SEER) database. A multivariate Cox proportional hazards model was used to analyze prognostic factors. Survival analysis was stratified based on stage T, stage N and immune subtypes. Results: Patients with T1cN2+ stage had the highest risk of death. However, in T1N1 stage cancers, compared with patients of other subtypes in T1mi/a-bN1 stage, the overall survival (OS) and breast cancer-specific survival (BCSS) of patients with T1mi/a-bN1 hormone receptor negative human epidermal growth factor receptor 2 positive (HR−HER2+) were significantly worse. HR+HER2− subtype patients showed a similar trend. Additionally, postoperative adjuvant chemotherapy (AC) was a favorable prognostic factor for OS in small-tumor breast cancer patients [hazard ratio (HR) =0.78, P0.05). Conclusions: In addition to T1cN2+ stage or HR−HER2− subtype, this study identified T1mi/a-bN1 HR−HER2+ subgroup as a high-risk type in small-tumor breast cancer. And small-tumor breast cancer patients do not usually benefit from AC. AC may not be recommended for certain subgroups, such as patients with pT1mi/a-bN0-1 HR+HER2− or pT1mi/a-bN0 HR−HER2−/HR+HER2+ can be exempted from chemotherapy.

9 January 2026 in Medicine
Verified
Journal Article
Open access
HZHuale Zhang
Huale Zhang
YZYizheng Zu
Yizheng Zu
XXXiaoyan Xiu
Xiaoyan Xiu
HYHuangchang Yi
Huangchang Yi
XXXia Xu
Xia Xu
YJYan Jianying
Yan Jianying
The immune-placental interaction could potentially contribute both causally and therapeutically to preeclampsia (PE). However, previous observational studies have not demonstrated a causal association between these 2 factors. Exploring the causal relationship between immune cells and PE provides genetic evidence that immune cells play a role in PE risk. Using a large dataset of genome-wide association studies, we conducted a bidirectional Mendelian randomization (MR) analysis to determine whether 731 immune cell signatures were correlated with PE, which included 4 types of immune signatures. After false discovery rate (FDR) correction, 3 immunophenotypes were identified to be significantly associated with PE risk: human leukocyte antigen on dendritic cells (odds ratio [OR] = 1.072, 95% confidence interval [CI] = 1.0352–1.110, P FDR = .012), absolute T cell count (OR = 1.477, 95% CI = 1.281–1.703, P FDR = 1.71 × 10 −5 ), and absolute lymphocyte count (OR = 1.514, 95% CI = 1.306–1.755, P FDR = 1.58 × 10 −5 ). Furthermore, PE did not affect immunophenotypes significantly after FDR adjustment, but 12 suggestive immunophenotypes were detected without FDR adjustment, including CD3 on activated and secreting CD4 regulatory T cell ( β = 0.467, P = .039), CD3 on CD39 + CD4 + T cell ( β = 0.508, P = .024), CD3 on CD45RA + CD4 + T cell ( β = 0.515, P = .022), CD3 on CD28 + CD45RA + CD8 + T cell ( β = 0.494, P = .028), CD3 on CD39 + CD8 + T cell ( β = 0.486, P = .029), CD45 on HLA DR + CD8 + T cell ( β = 0.518, P = .018), CD3 on secreting CD4 regulatory T cell ( β = 0.508, P = .025), CD25 on resting CD4 regulatory T cell ( β = 0.496, P = .018), CD4 on CD39 + activated CD4 regulatory T cell ( β = 0.445, P = .048), CD3 on CD28 + CD45RA − CD8 + T cell ( β = 0.498, P = .024), CD3 on effector memory CD4 + T cell ( β = 0.614, P = .007), and CD3 on activated CD4 regulatory T cell( β = 0.444, P = .049). Using genetic methods, this study uncovers the close relationship between immune cells and PE, which provides guidance for future clinical trials.